SCHEMBL16601877

SCHEMBL16601877

C[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O

nearest known ligand 0.36

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.36
LMNA P02545 1/20 0.36
GBA1 P04062 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13362009 1.00 THRB (0.36) THRBLMNAGBA1L3MBTL1
SCHEMBL25592953 1.00 THRB (0.36) THRBLMNAGBA1L3MBTL1
SCHEMBL23028656 1.00 THRB (0.36) THRBLMNAGBA1L3MBTL1
SCHEMBL13657213 1.00 THRB (0.36) THRBLMNAGBA1L3MBTL1
SCHEMBL18683146 0.95 THRB (0.36) THRBLMNAGBA1L3MBTL1
SCHEMBL16158586 0.95 THRB (0.36) THRBLMNAGBA1L3MBTL1
SCHEMBL9984795 0.95 THRB (0.36) THRBLMNAGBA1L3MBTL1
SCHEMBL24038360 0.95 THRB (0.36) THRBLMNAGBA1L3MBTL1
SCHEMBL13743009 0.83 THRB (0.38) THRBLMNA
SCHEMBL13301751 0.82 THRB (0.33) THRBLMNAGBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230338501-A1 LIVE-ATTENUATED RNA HYBRID VACCINE TECHNOLOGY ACCESS TO ADVANCED HEALTH INSTITUTE 2023-10-26 US disclosed
US-20230310569-A1 GENETICALLY-ADJUVANTED RNA VACCINES ACCESS TO ADVANCED HEALTH INSTITUTE 2023-10-05 US disclosed
US-20230310323-A1 CO-LYOPHILIZED RNA AND NANOSTRUCTURED LIPID CARRIER ACCESS TO ADVANCED HEALTH INSTITUTE 2023-10-05 US disclosed
US-20230310569-A1 GENETICALLY-ADJUVANTED RNA VACCINES ACCESS TO ADVANCED HEALTH INSTITUTE 2023-10-05 US disclosed
US-20230201111-A1 COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS THE JOHNS HOPKINS UNIVERSITY 2023-06-29 US disclosed
US-11680171-B2 Self-cleaning, dirt pick-up resistant compositions for roof coatings HENRY COMPANY, LLC (US) 2023-06-20 US disclosed
US-11642317-B2 Nanocrystals, compositions, and methods that aid particle transport in mucus THE JOHNS HOPKINS UNIVERSITY (US) 2023-05-09 US disclosed
US-20220054416-A1 NANOSTRUCTURED LIPID CARRIERS AND STABLE EMULSIONS AND USES THEREOF EUAGORE, LLC 2022-02-24 US disclosed
US-11219596-B2 Compositions and methods for ophthalmic and/or other applications THE JOHNS HOPKINS UNIVERSITY (US) 2022-01-11 US disclosed
US-11219597-B2 Compositions and methods for ophthalmic and/or other applications THE JOHNS HOPKINS UNIVERSITY (US) 2022-01-11 US disclosed
US-20190125758-A1 COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS THE JOHNS HOPKINS UNIVERSITY 2019-05-02 US disclosed
US-20190111002-A1 NOVEL VEHICLES FOR THE TRANSFECTION OF miRNAS UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) 2019-04-18 US disclosed
US-20180064641-A1 COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS THE JOHNS HOPKINS UNIVERSITY 2018-03-08 US disclosed
US-9827191-B2 Compositions and methods for ophthalmic and/or other applications THE JOHNS HOPKINS UNIVERSITY (US) 2017-11-28 US disclosed
US-20170266120-A1 NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS THE JOHNS HOPKINS UNIVERSITY 2017-09-21 US disclosed
US-9737491-B2 Nanocrystals, compositions, and methods that aid particle transport in mucus THE JOHNS HOPKINS UNIVERSITY (US) 2017-08-22 US disclosed
US-20170128378-A1 NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS THE JOHNS HOPKINS UNIVERSITY 2017-05-11 US disclosed
US-9513253-B2 Droplet actuators and techniques for droplet-based enzymatic assays ADVANCED LIQUID LOGIC, INC. (US) 2016-12-06 US disclosed
US-9513253-B2 Droplet actuators and techniques for droplet-based enzymatic assays ADVANCED LIQUID LOGIC, INC. (US) 2016-12-06 US disclosed
US-8992986-B2 Controlled release of biological entities AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) 2015-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064641-A1 COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS MUC1, PDE6C, STRA6 THRB 4019/4885LMNA 1275/4885GBA1 410/4885
US-20170128378-A1 NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS MUC1, SLC35A1, EPCAM THRB 4525/4885LMNA 1966/4885GBA1 1169/4885
US-20170266120-A1 NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS MUC1, SLC35A1, EPCAM THRB 4525/4885LMNA 1966/4885GBA1 1169/4885
US-11219597-B2 Compositions and methods for ophthalmic and/or other applications MUC1, PDE6C, STRA6 THRB 4019/4885LMNA 1275/4885GBA1 410/4885
US-20190125758-A1 COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS MUC1, PDE6C, STRA6 THRB 4019/4885LMNA 1275/4885GBA1 410/4885
US-20220054416-A1 NANOSTRUCTURED LIPID CARRIERS AND STABLE EMULSIONS AND USES THEREOF LIPC, LIPA, PLA2G2C THRB 4203/4885LMNA 304/4885GBA1 325/4885
US-20230201111-A1 COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS MUC1, PDE6C, STRA6 THRB 4019/4885LMNA 1275/4885GBA1 410/4885
US-11219596-B2 Compositions and methods for ophthalmic and/or other applications MUC1, PDE6C, STRA6 THRB 4019/4885LMNA 1275/4885GBA1 410/4885
US-20230310569-A1 GENETICALLY-ADJUVANTED RNA VACCINES TLR3, STING1, TLR9 THRB 2863/4885LMNA 4561/4885GBA1 646/4885
US-20190111002-A1 NOVEL VEHICLES FOR THE TRANSFECTION OF miRNAS TSG101, SLC67A1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 THRB 3162/4885LMNA 1877/4885GBA1 1509/4885
US-20230338501-A1 LIVE-ATTENUATED RNA HYBRID VACCINE TECHNOLOGY CHIA, SNRPE, LNPK THRB 4738/4885LMNA 668/4885GBA1 519/4885
US-11642317-B2 Nanocrystals, compositions, and methods that aid particle transport in mucus MUC1, SLC35A1, EPCAM THRB 4525/4885LMNA 1966/4885GBA1 1169/4885
US-20230310323-A1 CO-LYOPHILIZED RNA AND NANOSTRUCTURED LIPID CARRIER LIPC, RNMT, RNGTT THRB 4760/4885LMNA 337/4885GBA1 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.